Improving Definitive Therapy Among Patients with Methicillin-resistant Staphylococcus aureus Bloodstream Infections: Predictors of Early Therapeutic Switch to Linezolid or Daptomycin

BACKGROUND: Vancomycin is a first-line antibiotic for treating methicillin-resistant S. Aureus bloodstream infections (MRSA BSI), due to its activity against MRSA and low cost. If vancomycin fails, patients are often switched to daptomycin or linezolid. We aimed to determine predictors for switching...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweizer, Marin, Richardson, Kelly, Sarrazin, Mary Vaughan, Jones, Michael, Livorsi, Daniel, Nair, Rajeshwari, Goto, Michihiko, Alexander, Bruce, Beck, Brice, Perencevich, Eli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631808/
http://dx.doi.org/10.1093/ofid/ofx163.654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631808/
http://dx.doi.org/10.1093/ofid/ofx163.654

Ejemplares similares